Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart patch tracks blood sugar for homebound diabetes patients

NCT ID NCT05880810

Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether a continuous glucose monitor (CGM) helps control blood sugar better than standard finger-stick checks for people with diabetes who are recovering at home through Mayo Clinic's Advanced Care at Home program. About 100 participants will use the Dexcom G6 PRO, which sends real-time glucose data to a monitoring center. The goal is to see if this approach improves time in a healthy blood sugar range and reduces dangerous lows.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Continuous Glucose Monitor (Dexcom G6 PRO)
What this could lead to
If successful, this could show that remote monitoring of blood sugar helps people with diabetes manage their condition better while recovering at home.
What could go wrong
This is a small, early-stage study (100 participants) focused on feasibility, not a large-scale trial. The device may not work well for all patients, and results may not apply to those with severe complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who are admitted to Advanced Care at Home (ACH) Program and supposed to remain in ACH for at least 72 hours. * Patients with previous diagnosis of DM type 1 or type 2. * Patients taking subcutaneous (SQ) insulin either via multidose injections or SQ insulin pump. * Capable of giving signed informed consent Exclusion Criteria: * Actively treated for diabetes ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS). * Participants taking acetaminophen more than 4g per day or more than 1gm every 6 hours. * Participants with altered mental status. * Participants diagnosed with dementia. * Patients with suicidal ideations or experiencing suicidal behavior. * Patients with liver cirrhosis. * Patients with End Stage Renal Disease on dialysis bot hemodialysis or peritoneal dialysis. * Participants with allergy to medical grade adhesive or medical tape. * Participants taking hydroxyurea. * Participants who are pregnant, wanting to become pregnant, or nursing during study period. * Patients with a planned MRI within the following 10 days after admission to ACH. * Participants currently using continuous glucose monitor (CGM) to dose insulin or check glucose level. * Participants with diabetes mellitus (DM) treated with diet alone. * Participants with DM treated with oral hypoglycemic medications. * Participants with DM treated with one SQ insulin injection daily. * Participants enrolled in other studies addressing CGM use. * Participants physically or emotionally incapable of handling a cell phone with a smart display. * Participants with hearing impaired to a degree that they are not able to hear a smart phone alert or alarm. * Patients lacking WIFI or Cellular coverage needed to connect the monitoring cell phone to Internet network.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus 1 type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.